JMP Securities Upgrades Allergen (AGN) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- NVIDIA reports 9.3% passive stake in Nebius
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Allergen (AGN) Revenue Growth Plans Might Be Overly Ambitious
February 6, 2013 1:27 PM ESTJefferies today maintained a Hold rating on Allergen (NYSE: AGN) and raised its price target to $100.00 (from $95.00). Yesterday Allergan reported Q4 EPS of $1.15, $0.05 worse than the analyst estimate of $1.20. Adjusted for an R&D tax credit that got delayed until January, EPS would have been $1.21. Allergen... More
Allergan, Inc. (AGN) Misses Q4 EPS by 5c; Issues Mixed FY13 Outlook
February 5, 2013 9:02 AM ESTAllergan, Inc. (NYSE: AGN) reported Q4 EPS of $1.15, $0.05 worse than the analyst estimate of $1.20. Revenue for the quarter came in at $1.48 million versus the consensus estimate of $1.51 million.
Allergan, Inc. sees FY2013 EPS of $4.75-4.83, versus the consensus of $4.74. Allergan, Inc. sees FY2013... More
